VTVT
vTv Therapeutics Inc
30.60$
-4.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 12.4% | 97.4% | 95.6% | 72.9% | 40.6% | 30.6% | 48.8% | 61.3% | 81.5% | 96.7% | 99.6% | 100.0% | |
| 10.7% | 96.1% | 94.5% | 42.1% | 19.7% | 19.2% | 38.9% | 52.7% | 36.5% | 85.7% | 96.0% | 98.9% | |
| 10.7% | 96.1% | 94.5% | 42.1% | 19.7% | 19.2% | 38.9% | 52.7% | 36.5% | 85.7% | 96.0% | 98.9% | |
| – | 0.1% | – | 28.7% | 0.0% | 0.1% | 1.1% | 0.2% | 37.4% | 0.9% | 0.2% | – | |
| – | 0.0% | 0.0% | 0.6% | – | 2.7% | 2.5% | 0.4% | 0.0% | – | – | – | |
| 29.2% | 0.7% | 0.8% | 1.0% | 0.8% | 10.8% | 2.5% | 2.7% | 0.6% | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 3,951.5% | 185.2% | 266.9% | 641.1% | 1,068.0% | 195.4% | 74.4% | 40.2% | 82.4% | 268.4% | 62.6% | 28.3% | |
| 53.0% | 8.4% | 21.0% | 96.5% | 220.1% | 144.4% | 43.2% | 33.4% | 23.2% | 96.4% | 13.6% | 7.4% | |
| 1.2% | 3.7% | 15.3% | 15.3% | 109.6% | 67.8% | 1.6% | 1.7% | 1.1% | 3.3% | 0.4% | – | |
| 20.5% | 8.2% | 20.9% | 8.1% | 33.9% | 24.1% | 13.0% | 7.4% | 7.4% | 37.0% | 2.5% | 1.3% | |
| 278.1% | 0.0% | 20.3% | 54.9% | 74.0% | – | – | – | – | – | – | – | |
| -3,851.5% | -85.2% | -166.9% | -541.1% | -968.0% | -529.1% | -541.6% | -38.2% | -32.3% | -224.0% | 31.9% | 71.7% | |
| -3,851.5% | -214.1% | -395.4% | -999.6% | -2,732.6% | -2,520.2% | -1,961.2% | -976.8% | -798.9% | -2,550.8% | -783.2% | -363.4% | |
| 1.6% | 9.0% | 17.5% | 0.9% | 3.6% | 8.2% | 8.0% | 6.1% | 5.8% | 18.9% | 15.1% | 9.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.